Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

 
• By Joseph Haas
  
3d rendering Human Heart
Vericiguat showed ability to reduce hospitalizations in high-risk heart failure patients, but not a mortality benefit
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D